Syantra Inc. is a precision healthcare company that’s changing the way cancer detection and treatment are undertaken. Its flagship product, Syantra DX Breast Cancer, is a screening blood test for the detection of breast cancer that utilizes a suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result. Syantra DX represents an early entrant into the emerging molecular diagnostic sector. 

See the company’s progress -> Start Alberta

Left to right: Kenneth Fuh, PhD, MLT, Co-Founder & Director of Product Development, Bob Shepherd, Co-Founder, President & CEO, Kristina Rinker, PhD, PEng, Co-Founder & CSO, and Xiuling Wang, PhD Senior Scientist & Commercial Lab Manager.